Stay updated on SKI-G-801 Dose Study in AML Clinical Trial

Sign up to get notified when there's something new on the SKI-G-801 Dose Study in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SKI-G-801 Dose Study in AML Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:02:41.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the dosage or measurement related to the Phase I study of SKI-G-801 in patients with relapsed or refractory Acute Myeloid Leukemia (AML). This change may reflect an adjustment in the treatment protocol or outcome assessment within the clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:21:58.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.'
    Difference
    32%
    Check dated 2024-05-22T20:54:04.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:35:53.000Z thumbnail image

Stay in the know with updates to SKI-G-801 Dose Study in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SKI-G-801 Dose Study in AML Clinical Trial page.